6th Annual Pharma Marketing & Branding Excellence

Jacob Fleming Group25 - 26 January 2011, Milan, Italy.
Recently, behaviors of pharmaceutical marketing landscape, which includes health care providers, patients, and consumers are changing. Pharma companies are now favoring marketing through new media technologies like mobile-Web integration and online interactivity.

Following five successful annuals, Jacob Fleming Group invites you to the 6th Annual Pharma Marketing & Branding Excellence. Jacob Fleming Group has gathered worldwide Pharma marketing specialists who will share their knowledge with you. Hear them speak about the most powerful marketing strategies and network face-to-face.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from pharmaceutical industry. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Senior Vice President, Global Marketing, Bayer Healthcare, Germany
  • Head of Marketing, Specialty Care Business Unit, Pfizer, Finland
  • Director Strategic Marketing, Member of the Executive Committee, Abbott, Switzerland
  • Head of Marketing Scandinavia, UCB, Norway
  • Associate Director, EMEA Marketing, Baxter, Switzerland
  • Vice President, Franchise & Global Marketing Operations, Sanofi Pasteur, France
  • Founder and managing director of Webicina.com, Author of Scienceroll.com, University of Debrecen Medical School and Health
  • Senior Marketing Director, Pfizer, UK
  • Executive Director, Global Marketing Excellence, Johnson & Johnson, UK

Key topics:

  • Case studies from top pharmaceutical companies on how to target the most interesting segments through different channels
  • Understand, how to utilize the potential of mobile marketing & achieve greater brand interactivity and immediate response metrics for your brands.
  • Real life case studies on how to expand “traditional” e-detailing beyond its current limitations
  • Working case studies on how to develop and effective social media strategy
  • Find out how to achieve branding excellence in highly competitive market place
  • Experiences of top pharmaceutical companies on how to overcome barriers for effective closed loop marketing
  • Case studies on how to built sustainable brand equity in a commoditized market
  • Real life case studies on how to successfully select the most suitable brands for e-communication

Who should attend:
Senior Vice presidents, Vice presidents, Senior Executives, Global Heads, Heads, International Directors, Senior Directors, Directors, Senior Managers, Managers of: Marketing & Sales, Marketing, Marketing excellence, CRM, e-Marketing, Branding, Communication, Business Unit Directors, Strategic Planning, Commercial operations, Strategic Marketing, Brand management, Product Directors, Key Accounts, Advertising, Market research, Business Intelligence.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-marketing-branding-excellence?partner=worldpharmanewsMB

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...